Bionano Genomics Q3 revenue rises on optical genome mapping adoption

Overview

• Genome analysis solutions provider's Q3 revenue rose 12% yr/yr to $8.3 mln

• Gross margin improved to 48% from 46% a year earlier

• Operating expenses fell 12% to $10.5 mln in Q3

Outlook

• Bionano reiterates full-year 2026 revenue guidance of $31 mln to $33 mln

• Company expects broader clinical adoption of OGM supported by reimbursement and regulatory progress

• Bionano says momentum positions it for sustained growth in 2027 and beyond

Result Drivers

• OGM ADOPTION - Co said momentum in adoption of optical genome mapping (OGM) in clinical and commercial settings supported results

• REIMBURSEMENT AND REGULATORY PROGRESS - Co cited coverage and regulatory progress for OGM-based testing as helping build a clearer reimbursement pathway

• EVIDENCE BASE - Co noted new independent peer-reviewed studies demonstrating the value of OGM across a range of disorders

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

• Wall Street's median 12-month price target for Bionano Genomics, Inc. is $5.00, about 331% above its November 9 closing price of $1.16

Reuters Recommended Reads

• Nov 10 - Co-Diagnostics Q3 revenue rises, operating expenses fall 12%

• Nov 10 - Sweden's Genovis Q3 net sales rise 34% on record genomics segment

• Nov 9 - Quanterix Q3 revenue rises 6.3% sequentially

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)